CX Institutional’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$448K Buy
2,297
+757
+49% +$157K 0.01% 500
2026
Q1
$346K Sell
1,540
-321
-17% -$80K 0.01% 562
2025
Q4
$448K Buy
1,861
+104
+6% +$26.6K 0.01% 454
2025
Q3
$481K Buy
1,757
+222
+14% +$60.6K 0.01% 443
2025
Q2
$396K Buy
1,535
+5
+0.3% +$1.19K 0.01% 432
2025
Q1
$342K Buy
1,530
+97
+7% +$22.6K 0.01% 452
2024
Q4
$328K Buy
1,433
+2
+0.1% +$482 0.01% 422
2024
Q3
$349K Buy
1,431
+35
+3% +$7.82K 0.02% 435
2024
Q2
$267K Sell
1,396
-49
-3% -$9.94K 0.01% 483
2024
Q1
$286K Buy
1,445
+153
+12% +$28K 0.01% 469
2023
Q4
$222K Buy
+1,292
New +$199K 0.01% 472
2023
Q2
Sell
-966
Closed -$212K 534
2023
Q1
$212K Buy
+966
New +$210K 0.01% 467
2022
Q3
Sell
-664
Closed -$139K 997
2022
Q2
$139K Buy
+664
New +$141K 0.01% 492
2021
Q4
Sell
-458
Closed -$121K 793
2021
Q3
$121K Sell
458
-2
-0.4% -$547 0.01% 417
2021
Q2
$113K Buy
460
+125
+37% +$26.3K 0.01% 423
2021
Q1
$65K Buy
335
+18
+6% +$3.61K 0.01% 440
2020
Q4
$67K Buy
317
+57
+22% +$11.4K 0.01% 403
2020
Q3
$45K Buy
260
+19
+8% +$3.51K ﹤0.01% 399
2020
Q2
$46K Buy
241
+66
+38% +$10.8K 0.01% 348
2020
Q1
$26K Buy
175
+18
+11% +$2.87K ﹤0.01% 351
2019
Q4
$24K Hold
157
﹤0.01% 335
2019
Q3
$21K Buy
157
+38
+32% +$4.98K ﹤0.01% 369
2019
Q2
$15K Buy
119
+86
+261% +$9.53K ﹤0.01% 431
2019
Q1
$3K Buy
33
+27
+450% +$2.79K ﹤0.01% 646
2018
Q4
$1K Buy
+6
New +$643 ﹤0.01% 509

Other funds holding RMD

CX Institutional's RMD Position: Q2 2026 in Review

CX Institutional increased its ResMed (RMD) stake by 49% in Q2 2026, buying an estimated $157K and bringing the position to 2,297 shares worth $448K. The position accounts for 0.01% of the portfolio, ranked #500.

CX Institutional first reported a position in RMD in Q4 2018 and has held it in 25 quarters since. The position peaked at $481K in Q3 2025. 147 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • CX Institutional held 2,297 shares of ResMed worth $448K as of Q2 2026.
  • CX Institutional bought 757 ResMed shares in Q2 2026, an estimated $157K.
  • ResMed made up 0.01% of CX Institutional's portfolio in Q2 2026, its #500 holding.
  • CX Institutional first reported a position in ResMed in Q4 2018 and has held it in 25 quarters since.
  • CX Institutional's ResMed position peaked at $481K in Q3 2025.
  • 147 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.